# NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY

> **NIH NIH UM2** · JOHNS HOPKINS UNIVERSITY · 2021 · $5,854,958

## Abstract

Summary
The overarching goal of the research agenda described in this application is to position CoFAR as the
international leader in the study of food allergy, including optimal characterization of the disease and
development of the next generation of treatments. This next CoFAR will bring food allergy research to new
heights with cutting edge clinical and mechanistic studies focused on disease phenotypes and novel approaches
to prevention and treatment. The research agenda will be based first and foremost on the best possible science,
but to maximize productivity we will also need to plan judiciously so that all available resources can be used to
their utmost capacity. Therefore, the research agenda will need to carefully select and stage protocols based
not just on their potential to advance the field, but also with careful consideration regarding other novel treatments
that may be under development, and how one study may inform the next. Finally, the overall research strategy
will also need to balance the work load of the SACCC and each CRU in the consortium.
The three major aims of this program are to: 1) rapidly implement a food allergy registry study that will provide
the means to fully characterize and phenotype a large population of patients, determine true rates of reactions,
and serve as a recruitment source for clinical trials; 2) develop and implement a novel, cutting edge protocol for
the treatment of food allergy using a DNA-LAMP vaccine for the treatment of peanut allergy; and 3) choose and
develop additional protocols for inclusion in the consortium, especially related to other promising approaches in
development for either treatment or prevention. It is anticipated that a minimum of 3 protocols, including both
clinical trials and non-interventional studies, will be initiated and completed over the seven-year funding period,
and this could rise to 5 or even 6 protocols depending on the size, duration, and complexity of each study. In
addition, the agenda will work to fully integrate the Biomarker Facility and the Opportunity Fund into each of the
CoFAR protocols. If successful, this research agenda will define not just the next 7 years of CoFAR, but will also
establish the platform for the next decade(s) of food allergy research.

## Key facts

- **NIH application ID:** 10124262
- **Project number:** 5UM2AI130836-05
- **Recipient organization:** JOHNS HOPKINS UNIVERSITY
- **Principal Investigator:** A. Wesley Burks
- **Activity code:** UM2 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $5,854,958
- **Award type:** 5
- **Project period:** 2017-03-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10124262

## Citation

> US National Institutes of Health, RePORTER application 10124262, NEW HORIZONS IN THE PREVENTION AND TREATMENT OF FOOD ALLERGY (5UM2AI130836-05). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10124262. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*